CD8-positive T Cell Activation Pathway

The CD8-positive T cell activation pathway refers to the molecular and cellular processes by which naïve CD8+ T cells (also known as cytotoxic T lymphocytes, or CTLs) become activated in response to antigen presentation. This activation is crucial for immune defense against intracellular pathogens (such as viruses) and tumor cells. Activation begins when the T cell receptor (TCR) on a naïve CD8+ T cell recognizes a specific peptide antigen presented by major histocompatibility complex class I (MHC I) molecules on professional antigen-presenting cells (pAPCs), such as dendritic cells. The CD8 molecule acts as a coreceptor, binding to a region of MHC I, enhancing signal transduction. Full activation requires costimulatory signals—most notably through interactions between CD80/86 on APCs and CD28 on the T cell surface. Cytokines secreted by dendritic cells and activated helper (CD4+) T cells further support this process. Upon engagement, multiple intracellular pathways are triggered including MAPK and PI3K/Akt/mTOR. Once fully activated, clonal expansion occurs and differentiation into effector CTLs capable of killing infected or malignant target cells via release of cytotoxic granules. Most effectors die after pathogen clearance; some persist as memory subsets.

Other names

Cytotoxic T Lymphocyte Activation PathwayCTL Activation PathwayCD8+ T Cell ActivationCD8 T Cell Response

Various, depending on the specific agent: - Immunosuppressants: Inhibit T cell signaling pathways. - Checkpoint inhibitors: Block inhibitory signals, enhancing T cell activation. - CAR-T cells: Redirect T cell cytotoxicity to specific targets. - Vaccines/Adjuvants: Promote antigen presentation and costimulation, leading to T cell activation.